![](https://hitconsultant.net/wp-content/uploads/2024/04/Owlet-BabySat-Image-3.png)
What you should know:
– Owleta provider of intelligent infant monitoring technologies, announced a strategic partnership with Wheela leading virtual healthcare provider.
– Partnership allows Wheel’s network of clinicians to prescribe Owlet’s BabySat, an FDA-approved infant pulse oximeter. This innovative device, featuring a comfortable sock design, allows caregivers to effectively monitor their baby's health parameters at home. This collaboration promotes closer collaboration between parents and healthcare providers, ensuring optimal care for newborns.
Meeting critical needs
Each year, more than 450,000 babies leave neonatal intensive care units (NICUs) in the United States alone. Additionally, congenital heart disease (CHD) affects 40,000 newborns each year, and an estimated 58,000 to 80,000 children under the age of five require hospitalization due to respiratory syncytial virus (RSV).
Simplified access and reimbursement
The BabySat virtual telehealth platform, powered by Wheel, simplifies access to this vital monitoring tool. The platform integrates with durable medical equipment (DME) providers, making insurance billing easier and potentially offering up to 100% reimbursement for BabySat. This streamlined process significantly reduces the time and effort required for families to secure the device and receive insurance or HSA/FSA reimbursement.
“We are excited to announce our strategic partnership with Owlet, a leader in intelligent infant monitoring. This collaboration marks an important milestone in our mission to expand access to health care and simplify care delivery for all Americans, especially for growing families,” said Michelle Davey, CEO of Wheel . “Wheel's virtual care platform helps streamline access to home monitoring, making Owlet's BabySat pulse oximeter more convenient than ever for new parents.